Regeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference



Regeneron Pharmaceuticals, Inc.
December 27, 2017 at 9:30 AM EST

Regeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 27, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018.  The presentation is scheduled for 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) and may be accessed through the Company's web site,, on the 'Events and Presentations' page.  A breakout session will immediately follow the formal presentation and can also be accessed at  An archived version of the presentation and the breakout session will be available for 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, Regeneron's unique ability to consistently translate science into medicine has led to six FDA-approved treatments and over fifteen product candidates, all of which were homegrown in its laboratories. Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit or follow @Regeneron on Twitter.

Contact Information:

Investor Relations               

Corporate Communications

Manisha Narasimhan, PhD         

Hala Mirza




Cision View original content:

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media